

Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort

Emeline Tabouret^{1,2} · Anh Tuan Nguyen³ · Caroline Dehais⁴ · Catherine Carpentier⁵ · François Ducray^{6,7} · Ahmed Idbaih^{4,5} · Karima Mokhtari^{4,5,8} · Anne Jouvett⁹ · Emmanuelle Uro-Coste^{10,11} · Carole Colin² · Olivier Chinot^{1,2} · Hugues Loiseau¹² · Elisabeth Moyal^{13,14,15} · Claude-Alain Maurage¹⁶ · Marc Polivka¹⁷ · Emmanuèle Lechapt-Zalcman^{18,19} · Christine Desenclos²⁰ · David Meyronet^{7,9} · Jean-Yves Delattre^{4,5} · Dominique Figarella-Branger^{2,3} · For POLA Network

Received: 20 July 2016 / Revised: 12 August 2016 / Accepted: 22 August 2016
© Springer-Verlag Berlin Heidelberg 2016

Abstract The new WHO classification of diffuse gliomas has been refined and now includes the 1p/19q codeletion, *IDH1/2* mutation, and histone H3-K27M mutation. Our objective was to assess the prognostic value of the updated 2016 WHO classification in the French POLA cohort. All cases of high-grade oligodendroglial tumors sent for central pathological review and included into the French nationwide POLA cohort were reclassified according to the updated 4th WHO classification. In total, 1041 patients were included, with a median age at diagnosis of 50.4 years

(range 17.1–84.4). Based on the new histomolecular classification, diagnoses included anaplastic oligodendroglioma *IDH* mutant and 1p/19q-codeleted (32.5 %), anaplastic astrocytoma *IDH* mutant (*IDH*^{mut}) (11.0 %), anaplastic astrocytoma *IDH* wild type (*IDH*^{wt}) (5.3 %), glioblastoma *IDH*^{mut} (17.1 %), and glioblastoma *IDH*^{wt} (33.2 %). Ten patients presented with a diffuse midline tumor, H3 K27M mutant. The new WHO classification was prognostic for progression-free survival (PFS) and overall survival (OS) ($p < 0.001$). We did not find prognosis differences between grades III and IV for *IDH*^{mut} 1p/19q intact and *IDH*^{wt} gliomas in univariate and multivariate analyses. Among anaplastic astrocytoma *IDH*^{wt}, cases with chromosome arm 7p gain and 10q loss (55 %) had shorter PFS than the others ($p = 0.027$). In conclusion, the new WHO histomolecular

These results were presented, in part, at the 2016 ASCO annual meeting in poster discussion (abstract number 2015).

Electronic supplementary material The online version of this article (doi:10.1007/s00401-016-1611-8) contains supplementary material, which is available to authorized users.

✉ Dominique Figarella-Branger
dominique.figarella-branger@univ-amu.fr

- ¹ APHM, Hôpital de la Timone, Service de Neurooncologie, Marseille, France
- ² Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France
- ³ APM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France
- ⁴ AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière, Charles Foix, Service de Neurologie 2-Mazarin, 75013 Paris, France
- ⁵ Inserm U1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR_S1127, Institut du Cerveau et de la Moelle épinière, ICM, 75013 Paris, France
- ⁶ Hospices Civils de Lyon, Hôpital Pierre Wertheimer, Service de Neurooncologie, Bron, France
- ⁷ Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France

- ⁸ AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France
- ⁹ Centre de pathologie et de neuropathologie Est, Bron, France
- ¹⁰ CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France
- ¹¹ Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, Toulouse, France
- ¹² CHU Bordeaux, Hôpital Pellegrin, Service de Neurochirurgie, Bordeaux, France
- ¹³ Department of Radiation Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse, Oncopôle, Toulouse, France
- ¹⁴ Université Toulouse III Paul Sabatier, Toulouse, France
- ¹⁵ INSERM U1037, Centre de Recherches contre le Cancer de Toulouse, Toulouse, France
- ¹⁶ CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France

classification of diffuse gliomas presented with high prognostic value. Grading was not discriminant between grade III and IV high-grade gliomas.

Keywords Diffuse glioma · 2016 WHO classification · *IDH1/2* mutation · 1p/19q codeletion

Background

Diffuse gliomas are the most frequent and aggressive primary brain tumors in adults, and until recently, they were classified according to the 4th edition of the World Health Organization (WHO) classification published in 2007 [16]. The former classification took into account the histological subtype (astrocytic, oligodendrocytic, and oligoastrocytic) and grade, ranging from grade II to grade IV glioblastoma, which is a highly malignant invasive and angiogenic tumor. Inconstant reproducibility and interobserver variability were critical points of this classification, relying on pathological criteria only [5]. Molecular understanding of gliomagenesis was first improved with the identification of the 1p/19q codeletion, associated with an oligodendroglial phenotype and with a better prognosis [26]. This alteration appeared to be a predictive marker of response to procarbazine, CCNU, and vincristine (PCV) [2, 3]. More recently, integrated genomic analysis of gliomas has identified *IDH* mutation as the key alteration in gliomagenesis [20]. *IDH* mutation characterizes adult grade II and III gliomas as well as secondary glioblastoma [28] and is of prognostic significance. Therefore, it was an appropriate time to introduce molecular markers into the WHO classification [17].

Updating the 4th WHO classification of tumors of the central nervous system (CNS) has yielded major changes in the group of glial tumors [18]. The updated classification stratifies the group of “diffuse astrocytic and oligodendroglial tumors” according to the occurrence of two major genetic alterations: *IDH* mutation and 1p/19q codeletion. It recognizes “diffuse midline glioma, H3 K27M mutant” as a new entity. In addition, according to this new classification, the diagnosis of mixed glioma, a category that was not

sharply defined until recently and was subject to high interobserver discordance [1], is strongly discouraged.

In France, since 2008, a dedicated program has been set up for more homogeneous management of de novo adult high-grade glioma with an oligodendroglial component [prise en charge des oligodendrogliomes anaplasiques (POLA network)]. The aim of the program inter alia is to provide a pathological centralized review of the cases and centralized molecular analysis.

The aim of this study was to reclassify the entire POLA cohort according to the recent update of the 4th WHO classification of CNS tumors to analyze its prognostic and discriminant values.

Materials and methods

Patients

All 1041 patients who were sent for a central pathological review because of the suspicion of diffuse high-grade gliomas with an oligodendroglial component and included into the French nation-wide POLA cohort on June 6, 2015 were included in this study. For all cases, formalin-fixed, paraffin-embedded (FFPE) tumor tissue was available for pathological and immunohistochemical analyses. In addition, frozen material was available in up to 974 cases. Initial WHO 2007 diagnosis was retained after centralized review of all cases by four national neuropathological experts. At the time of the review process, the experts were blind of 1p19q status determination, and for cases enrolled before 2010, *IDH1*R132H expression was also unknown.

Patients prospectively included into the POLA cohort provided their written consent for clinical data collection and genetic analysis according to national and POLA network policies.

Clinical characteristics of the cohort are summarized in Table 1.

Pathological review according to the 2007 WHO classification and immunohistochemistry

After the initial diagnosis of high-grade glioma with an oligodendroglial component by local pathologists, cases were centrally reviewed and included in the prospective POLA cohort. In addition, automated IHC was performed on 4-μm-thick FFPE sections with an avidin–biotin–peroxidase complex on Benchmark XT (Ventana Medical System Inc, Tucson AZ, USA) using the Ventana Kit including DAB reagent to search for the expression of *IDH1* R132H (Dianova, H09), *P53* (DAKO, DO.7), and *ATRX* (SIGMA, polyclonal).

¹⁷ AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France

¹⁸ CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France

¹⁹ CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France

²⁰ CHU Amiens, Service de neurochirurgie, Hôpital Nord, Amiens, France

DNA extraction, single-nucleotide polymorphism (SNP) arrays, and comparative genomic hybridization (CGH) arrays

Following the manufacturer's recommendations, tumor DNA was extracted from frozen tissue, if available, or from FFPE samples using the iPrep ChargeSwitch® Forensic Kit. Qualification and quantification of tumor DNA were performed using a NanoVue spectrophotometer and gel electrophoresis, respectively. In 974 cases, the genomic profile and assessment of the 1p/19q codeletion status were determined as described previously [7]. When the quantity of DNA was insufficient to perform SNP or CGH arrays ($n = 6$), microsatellite analysis was conducted, and microsatellite analyses (LOH) of chromosomes 1p and 19q were assessed via PCR techniques described elsewhere [13]. In addition, particular attention was paid to the following alterations: chromosome 7 gain, chromosome 10 loss, *PTEN* deletion, and *EGFR* amplification.

IDH1, IDH2, and TERT mutation status

When the results of IDH1R132H immunohistochemistry were negative or unreliable, the status of *IDH1* and *IDH2* mutation was addressed by direct sequencing using the Sanger method and primers, as described previously [10]. *TERT* mutation status was also addressed in 771 cases by direct sequencing using the Sanger method and primers, as described previously [14].

Statistical analysis

SNP and CGH array analyses were performed as described previously [12]. For all arrays, genomic imbalances were classified as loss, gain, homozygous deletion, or amplification. For correlation analysis, the Chi-square test (or Fisher's exact test) was used to compare variables when they were scored as positive or negative. Continuous variables were compared using the Mann–Whitney *U* test. Progression-free survival (PFS) was defined as the time from the date of surgery to recurrence or death from any cause. Overall survival (OS) was defined as the time from the date of surgery to death from any cause. The Kaplan–Meier method was used to estimate survival distributions. Log-rank tests were used for univariate comparisons. Cox proportional hazards models were used for multivariate analyses and for estimating hazard ratios in survival regression models. Multivariate analysis included all variables with a p value <0.05 in univariate analyses. All statistical tests were two-sided, and the threshold for statistical significance was $p = 0.05$. Analyses were conducted using PASW Statistics version 20 (IBM SPSS Inc., Chicago, IL, USA).

Results

Patient characteristics and pathological diagnosis

In total, 1041 cases who were addressed to a central pathological review because of the suspicion of diffuse high-grade gliomas with an oligodendroglial component and were diagnosed between September 2008 and June 2015 were included (Table 1). The median follow-up period was 19.0 months (range 0.1–77.0 months). The median age at diagnosis was 50.4 years (range 17.1–84.4). Only 7 % of patients presented with an altered functional status, while 14 % had cognitive disorders at diagnosis. Half of the patients benefited from gross total resection, and the first-line treatment corresponded to the association of chemotherapy and radiotherapy for more than 65 % of patients (Table 1). According to the 2007 WHO classification, these 1041 cases were classified as follows: anaplastic oligodendroglioma (31.6 %), anaplastic oligoastrocytoma (27.6 %), anaplastic astrocytoma (7 %), glioblastoma with an oligodendroglial component (14.9 %), and glioblastoma (18.9 %).

Molecular data and histomolecular classification according to the 2016 WHO classification (Fig. 1)

Sixty percent of patients presented with *IDH* mutant (*IDH*^{mut}) tumors, and 34 % of patients presented with 1p/19q-codeleted tumors (34.5 %) (Supplementary Table 1). Among the 626 patients with *IDH*^{mut} tumor, 599 presented with *IDH1*^{mut} [R132H: 562 (94 %), R132C: 15, R132G: 13, R132S: 6, and R132L: 3] and 27 presented with *IDH2*^{mut} (R172K: 19, R172M: 5, R172I: 1, R172S: 1, and R172 W: 1). Forty-six percent of patients presented with P53 immunostaining in nuclei above 10 %. Immunostaining of ATRX was not detected in 90 % of patients with *IDH*^{mut} without 1p/19q-codeleted glioma, (Supplementary Table 2).

Based on the new updated WHO classification (Table 2), the reclassification of the POLA cases showed a substantial change in grade (IV versus III) with an increase in glioblastoma diagnoses (50.3 versus 33.8 %), while the frequency of oligodendroglioma remained stable. Thus, the 1041 cases were reclassified as anaplastic oligodendroglioma *IDH*^{mut} 1p/19q-codeleted (32.5 %), anaplastic astrocytoma *IDH*^{mut} (10.9 %), anaplastic astrocytoma *IDH*^{wt} (5.3 %), glioblastoma *IDH*^{mut} (17.2 %), and glioblastoma *IDH*^{wt} (33.1 %). Ten patients presented a midline tumor with the histone H3 K27M mutation (Fig. 1).

Mixed anaplastic oligoastrocytoma and glioblastoma with an oligodendroglial component, which have been removed from the new classification, were reclassified as anaplastic oligodendroglioma *IDH*^{mut} 1p/19q-codeleted (16.1 %), anaplastic astrocytoma *IDH*^{mut} (14.7 %),

Table 1 Patient characteristics

Factors	N	%
Age (median, range, years)	50.4 (17.1–84.4)	
Gender (men/women)	549/397	58/42
Unknown	95	
KPS		
<60	5	1.3
60	22	5.2
70	48	11.4
80	60	14.3
90–100	285	67.8
Unknown	621	
Patients with cognitive disorders at diagnosis	115	14
Unknown	215	
Type of surgery ^a		
Gross total resection	474	51.8
Biopsy or partial resection	440	48.2
Unknown	127	
First-line treatment		
None	26	2.9
Radiotherapy	132	14.8
PCV + radiotherapy	151	16.9
Stupp protocol	450	50.4
Chemotherapy alone	78	8.7
Other	55	6.2
Unknown	149	
Pathological characteristics		
Mitosis without necrosis nor MVP	234	22.4
MVP without necrosis	456	43.8
Necrosis and MVP	351	33.8
Immunostaining and molecular alterations		
IDH1/2 ^{mut}	626/1041	60.1
1p/19q codeletion	338/980	34.5
ATRX loss	281/772	63.5
P53 expression >10 %	484/1041	46.5
H3 K27M mutation	10	1.0
TERT mutation	457/771	59.3
7p gain and 10q loss	246/976	25.2
PTEN loss	217/965	22.5
EGFR amplification	124/966	12.8

KPS Karnofsky performance status, PCV procarbazine–CCNU–vincristine, MVP microvascular proliferation; IDH1/2^{mut} IDH1/2-mutation

^a Type of surgery was determined by operating report of neurosurgeon

anaplastic astrocytoma IDH^{wt} (3.0 %), glioblastoma IDH^{mut} (37.1 %) glioblastoma IDH^{wt} (28.6 %), and midline glioma with the histone H3 K27M mutation (0.5 %) (Supplementary Table 3; Fig. 2).

Prognostic value of WHO classifications and grading

The median PFS and OS were 23.8 months [95 % confidence interval (CI): 21.1–26.5] and 62.0 months (95 % CI: 52.0–72.0), respectively. Both the 2007 WHO and the new updated WHO classifications of gliomas were prognostic for PFS and OS ($p < 0.001$) (Fig. 3; Table 3). Moreover, the new WHO 2016 classification presented with high hazard ratio both for PFS and OS (Table 3), higher than those observed for the previous 2007 classification, reinforcing the discriminative value of this new histomolecular classification. Grading (III versus IV) for IDH^{mut} 1p/19q intact gliomas was not prognostic in either univariate analysis (PFS: $p = 0.505$; OS: $p = 0.838$) (Fig. 3b, d) or multivariate analysis (adjusted by the age, type of surgery, and first-line treatment). In addition, no prognostic difference was observed between grade III and IV IDH^{wt} gliomas (Fig. 3b, d) in terms of PFS ($p = 0.449$) and OS ($p = 0.335$) in univariate and multivariate analyses (adjusted by the age, type of surgery, and first-line treatment). Among patients with anaplastic astrocytoma IDH^{wt}, cases presenting with 7p gain and 10q loss (55 %, Supplementary Table 4) had a worse prognosis than others in terms of PFS ($p = 0.027$) but not OS. This finding suggests that anaplastic astrocytoma IDH^{wt} remains a heterogeneous subgroup.

TERT prognostic value

TERT mutation status was available for 771 patients. Among them, 59 % ($N = 457$) presented with mutated TERT (TERT^{mut}) tumor: 133 patients with the C250T mutation, 321 patients with the C228T mutation, and 3 patients with both. A TERT^{mut} was observed in 93 % (257/275), 10 % (22/222), and 65 % (176/269) of anaplastic oligodendroglioma IDH^{mut} 1p/19q-codeleted, IDH^{mut} 1p/19q intact gliomas, and IDH^{wt} gliomas, respectively. No prognostic impact of TERT^{mut} was observed for OS. TERT^{mut} was associated with a worse PFS for glioblastoma IDH^{wt} patients, but no PFS impact was observed in grade III IDH^{wt} gliomas, while in this last subgroup, TERT^{mut} was associated with the 7p gain and 10q loss ($p = 0.018$) (Supplementary Table 4).




Fig. 1 Molecular and immunostaining alterations and patient age and survival (in months) according to the new 2016 WHO classification of gliomas. *O* oligodendroglioma, *A* astrocytoma, *GB* glioblastoma, *K27M* diffuse midline glioma with histone H3 K27M mutation, *CODEL* 1p/19q codeletion, *IDH-MUT* *IDH1/2* mutant, and *IDH-WT* *IDH1/2* wild type

Discussion

In this study, we were able to reclassify all the POLA series according to the 2016 WHO classification of brain tumors. Notably, the percentage of each category of diffuse, adult high-grade gliomas recorded in this study does not reflect the normal distribution of malignant glioma subgroups because of the inclusion criteria in the POLA network, i.e., adult malignant glioma with an oligodendroglial component. Based on these results, our first observation was a switch in grading (III versus IV) with an increased frequency of glioblastoma. Although this switch was recorded for different entities, it was more frequent for the cases initially diagnosed as grade III oligoastrocytoma, because up to 50 % cases were reclassified as glioblastoma (*IDH^{mut}* or *IDH^{wt}*). Our second observation was that the new updated

toma, *K27M* diffuse midline glioma with histone H3 K27M mutation, *CODEL* 1p/19q codeletion, *IDH-MUT* *IDH1/2* mutant, and *IDH-WT* *IDH1/2* wild type

2016 WHO classification had a high prognostic value. Our third observation was that grading III versus IV was prognostic for neither *IDH^{mut}* 1p/19q intact gliomas nor *IDH^{wt}* gliomas, which brings into question the relevance of grade in these tumors.

In the POLA series, more than 400 cases were previously classified according to the 2007 WHO as mixed gliomas, a diagnostic category that should be avoided according to the 2016 classification. Of note, recommendation to limit mixed glioma diagnosis was reinforced by the recent publications on glioblastoma with oligodendroglial component (GBMO), which suggested that GBMO corresponded to various and distinct molecular entities [6, 9]. We were able to reclassify these cases on the basis of molecular characteristics. Most diffuse high-grade gliomas are now stratified according to *IDH* mutation and 1p/19q codeletion. In the present series,

IDH1R132H immunostaining was sufficient to assess the *IDH* status in 562 cases (94 %) showing strong IDH1R132H expression, a frequency similar to that observed previously [25]. In the remaining cases, IDH sequencing revealed *IDH1* mutation in 37 cases and *IDH2* mutation in 27. Loss of nuclear ATRX expression was almost mutually exclusive from 1p/19q codeletion. We observed only three cases that demonstrated both alterations, even after repeating

Table 2 Reclassification of the 1041 cases of the French POLA cohort according to the updated 4th WHO classification


Integrated diagnoses	N = 1041	%
Anaplastic oligodendroglioma, <i>IDH</i> ^{mut} and 1p/19q codeletion	334	32.1
Anaplastic oligodendroglioma, <i>IDH</i> ^{wt} and 1p/19q codeletion	4	0.4
Anaplastic astrocytoma, <i>IDH</i> ^{mut}	114	10.9
Anaplastic astrocytoma, <i>IDH</i> ^{mut} ATRX lost	107	
Anaplastic astrocytoma, <i>IDH</i> ^{mut} ATRX preserved	6	
Anaplastic astrocytoma, <i>IDH</i> ^{mut} , ATRX unknown	1	
Anaplastic astrocytoma, <i>IDH</i> ^{wt}	55	5.3
With 7p+/10q–	30	
Glioblastoma, <i>IDH</i> ^{mut}	178	17.2
Glioblastoma, <i>IDH</i> ^{mut} ATRX lost	151	
Glioblastoma, <i>IDH</i> ^{mut} ATRX preserved	21	
Glioblastoma, <i>IDH</i> ^{mut} , ATRX unknown	6	
Glioblastoma, <i>IDH</i> ^{wt}	346	33.1
Diffuse midline glioma, H3 K27M-mutant	10	1.0

IDH^{mut} *IDH1/2*-mutant, *IDH*^{wt} *IDH1/2*-wild type, 7p+/10q– chromosome arm 7p gain with chromosome arm 10q loss

immunostaining and CGH analysis. These cases may correspond to the extremely rare “true” mixed glioma [11]. Although most *IDH*^{mut} (1p/19q-intact) gliomas exhibited loss of ATRX (249/276), we observed 27 cases in which ATRX nuclear expression was retained. This rare molecular phenotype has been reported previously [23]. Another rare molecular phenotype was represented by loss of nuclear ATRX expression in *IDH*^{wt} gliomas (20 cases); among these, a histone mutation was recorded in five of the 16 cases studied. We also observed that anaplastic oligodendroglioma *IDH*^{wt} and 1p/19q-codeleted are exceptional (four cases). This last result further confirmed that almost all 1p/19q-codeleted oligodendrogliomas are *IDH* mutants, although some exceptions exist [3]. Because CGH analysis was performed in all cases, in addition to the 1p/19q status, we had information regarding the main alterations that characterize glioblastomas, i.e., the association of chromosome arm 7p gain and 10q loss. We observed that among the 55 anaplastic astrocytomas *IDH*^{wt}, 30/55 exhibited these alterations (7p gain and 10q loss). Some authors suggested that such cases should be classified as glioblastoma [23, 24, 27]. Reuss et al. reported that up to 78 % of anaplastic astrocytoma *IDH*^{wt} presented with glioblastoma molecular alterations, while 9 % were diagnosed as glioblastoma *H3F3A* mutated in their series [21]. However, in this study, only 55 % of anaplastic astrocytoma *IDH*^{wt} demonstrated glioblastoma molecular alterations, suggesting that all anaplastic *IDH*^{wt} astrocytoma should not be classified as glioblastoma.

Interestingly, we found that the 2016 WHO classification was highly accurate in predicting survival, confirming the value of adding molecular characteristics. However, this classification has some limitations. We observed that

Fig. 2 Repartition of the mixed oligoastrocytomas according to the updated 2016 WHO classification






Fig. 3 Progression-free survival and overall survival according the previous WHO classification (**a**, **c**) and updated classification (**b**, **d**). AO anaplastic oligodendroglioma, AA anaplastic astrocytoma, AOA

anaplastic oligoastrocytoma, GB glioblastoma, GBMO glioblastoma with oligodendroglial component, IDH^{mut} IDH1/2 mutant, and IDH^{wt} IDH1/2 wild type

the same class of glioblastoma could refer to distinct entities, while different designations (anaplastic astrocytoma and glioblastoma) could refer to patient groups with similar outcomes. As previously reported for grade II and III gliomas [4, 27], we observed that grade III and IV adult diffuse gliomas can be divided into three major groups having distinct prognoses according to the *IDH* and 1p/19q codeletion status. The best prognosis was observed in anaplastic oligodendroglioma IDH^{mut} 1p/19q-codeleted, the worst prognosis was observed in IDH^{wt} gliomas, and an intermediate prognosis was observed in IDH^{mut} 1p/19q intact gliomas. We have also reported a distinct age repartition between these three main groups (Fig. 1). Interestingly, among the groups of IDH^{wt} gliomas and IDH^{mut} 1p/19q intact gliomas, grade III versus IV did not impact survival in our series. The relevance of the grading prognostic impact in the context of molecular subgroups was

previously questioned in a limited number of recent studies. If the impact of grading between grade II and III gliomas was already challenged by several studies [19, 27], the current data remained more contradictory between grade III and IV gliomas [8, 22], suggesting, in these publications, a possible remaining prognostic value of grading. However, these studies differed from ours on several points, notably regarding the diagnosis reviewing process and the patient treatments which were more homogenous in our series, since the POLA network also provided treatment recommendations. Taken together, grading from II to IV may be questioned for all IDH^{wt} and IDH^{mut} 1p/19q intact gliomas. This is of high importance because the definition of anaplasia in IDH^{wt} and IDH^{mut} 1p/19q intact gliomas relies on the mitotic index, another parameter that is not always reproducible. Thus, based on these results, we observed the occurrence of three main molecular subgroups with distinct

Table 3 Discriminative value of the previous and new glioma WHO classification based on the hazard ratio (HR) and 95 % confidence interval (95 % CI) for each diagnosis, determined by Cox survival analysis for progression-free survival (PFS) and overall survival (OS)

	PFS		OS	
	HR	95 % CI	HR	95 % CI
Previous classification				
AO	Reference diagnosis		Reference diagnosis	
AOA	1.495	1.130–1.978	2.259	1.523–3.352
AA	2.705	1.765–4.147	4.340	2.495–7.552
GBMO	2.799	2.084–3.759	4.214	2.819–6.301
GB	4.933	3.769–6.457	7.534	5.208–10.898
New classification				
AO 1p/19q-codeleted	Reference diagnosis		Reference diagnosis	
AA <i>IDH</i> ^{mut}	1.603	1.059–2.428	3.588	1.938–6.644
GB <i>IDH</i> ^{mut}	1.848	1.328–2.570	3.493	2.065–5.909
AA <i>IDH</i> ^{wt}	5.025	3.209–7.866	11.02	5.889–20.625
GB <i>IDH</i> ^{wt}	6.135	4.780–7.873	14.708	9.678–22.333

AO anaplastic oligodendroglioma, AA anaplastic astrocytoma, GB glioblastoma, GBMO glioblastoma with oligodendroglial component, AOA anaplastic oligoastrocytoma, *IDH*^{mut} *IDH1/2*-mutant, *IDH*^{wt} *IDH1/2*-wild type

prognoses, which may represent a new basis for inclusion criteria in neurooncological clinical trials [15].

Recent studies have emphasized the usefulness of *TERT* promoter mutation to stratify gliomas [14, 27]. In this study, we observed that *TERT* mutation has a bimodal distribution: in *IDH*^{mut} gliomas, it is mainly associated with 1p19q codeletion (although some exceptions exist as shown here and by others [4, 27]), and it is also recorded in a large number of adult *IDH*^{wt} gliomas. Moreover, we observed that *TERT* mutation was associated with shorter PFS in the subgroup of glioblastoma *IDH*^{wt}. In contrast, *TERT* mutation failed to stratify the anaplastic *IDH*^{wt} gliomas. Whether *TERT* promoter mutation in association with *IDH* mutation is sufficient to stratify adult gliomas requires further investigation.

Conclusion

In conclusion, the POLA series reported in this study shows that the 2016 WHO classification of adult diffuse malignant gliomas provides a high prognostic value, allowing the identification of three main subgroups for future neurooncological trials. It also clarifies the limits of grading (III versus IV) in the group of *IDH*^{mut} 1p/19q intact and *IDH*^{wt} gliomas.

Acknowledgments The POLA network is funded by the French Institut National du cancer and part of the national program Carte d'Identité des Tumeurs® (CIT) (<http://cit.ligue-cancer.net>) funded and

developed by the Ligue Nationale contre le Cancer. Cases from Marseille were retrieved from the AP-HM tissue bank AC 2013-1786 and were included in the SIRIC-Marseille Glioma program (Grant INCa-DGOS-Inserm 6038). All patients were included in the French POLA network. Institut Universitaire du Cancer (IUC).

Compliance with ethical standards

Funding The POLA network is funded by the French Institut National du cancer and part of the national program Carte d'Identité des Tumeurs® (CIT) (<http://cit.ligue-cancer.net>) funded and developed by the Ligue Nationale contre le Cancer.

Conflict of interest E. Tabouret has received research grants from Novartis®. A. Idhah has received research grants from Carthera and honoraria from Roche® and Bristol-Meyers Squibb®. O. Chinot has received Honoraria from Roche®. Other authors declare that they have no conflicts of interest.

References

- van den Bent MJ (2010) Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. *Acta Neuropathol (Berl)* 120:297–304. doi:10.1007/s00401-010-0725-7
- van den Bent MJ, Brandes AA, Taphoorn MJB, Kros JM, Kouwenhoven MCM, Delattre J-Y, Bernsen HJJA, Frenay M, Tijsen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WNM, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. *J Clin Oncol Off J Am Soc Clin Oncol* 31:344–350. doi:10.1200/JCO.2012.43.2229

3. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. *J Clin Oncol Off J Am Soc Clin Oncol* 31:337–343. doi:[10.1200/JCO.2012.43.2674](https://doi.org/10.1200/JCO.2012.43.2674)
4. Network Cancer Genome Atlas Research, Brat DJ, Verhaak RGW, Aldape KD, Yung WKA, Salama SR, Cooper LAD, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Nouchmeh H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenbergh SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson HL, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tamuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhi R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabuoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG, Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, McLendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpaccia L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DPC, Unterberg A, Valurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J (2015) Comprehensive, integrative genomic analysis of diffuse low-grade gliomas. *N Engl J Med* 372:2481–2498. doi:[10.1056/NEJMoa1402121](https://doi.org/10.1056/NEJMoa1402121)
5. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. *Cancer* 79:1381–1393
6. Figarella-Branger D, Mokhtari K, Colin C, Uro-Coste E, Jouvet A, Dehais C, Carpentier C, Villa C, Maurage C-A, Eimer S, Polivka M, Vignaud J-M, Laquerriere A, Sevestre H, Lechapt-Zalcman E, Quintin-Roué I, Aubriot-Lorton M-H, Diebold M-D, Viennet G, Adam C, Loussouarn D, Michalak S, Rigau V, Heitzmann A, Vandenbos F, Forest F, Chiforeanu D, Tortel M-C, Labrousse F, Chenard M-P, Nguyen AT, Varlet P, Kemeny JL, Levillain P-M, Cazals-Hatem D, Richard P, Delattre J-Y, POLA Network (2015) Prognostic relevance of histomolecular classification of diffuse adult high-grade gliomas with necrosis. *Brain Pathol Zurich Switz* 25:418–428. doi:[10.1111/bpa.12227](https://doi.org/10.1111/bpa.12227)
7. Figarella-Branger D, Mokhtari K, Dehais C, Jouvet A, Uro-Coste E, Colin C, Carpentier C, Forest F, Maurage C-A, Vignaud J-M, Polivka M, Lechapt-Zalcman E, Eimer S, Viennet G, Quintin-Roué I, Aubriot-Lorton M-H, Diebold M-D, Loussouarn D, Lacroix C, Rigau V, Laquerrière A, Vandenbos F, Michalak S, Sevestre H, Peoch M, Labrousse F, Christov C, Kemeny J-L, Chenard M-P, Chiforeanu D, Ducray F, Idbaih A, POLA Network (2014) Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. *Neuro-Oncol* 16:1244–1254. doi:[10.1093/neuonc/nou047](https://doi.org/10.1093/neuonc/nou047)
8. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. *Acta Neuropathol (Berl)* 120:707–718. doi:[10.1007/s00401-010-0781-z](https://doi.org/10.1007/s00401-010-0781-z)
9. Hinrichs BH, Newman S, Appin CL, Dunn W, Cooper L, Pauly R, Kowalski J, Rossi MR, Brat DJ (2016) Farewell to GBM-O: genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups. *Acta Neuropathol Commun* 4:4. doi:[10.1186/s40478-015-0270-7](https://doi.org/10.1186/s40478-015-0270-7)
10. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillemin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre J-Y (2010) IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. *Neurology* 75:1560–1566. doi:[10.1212/WNL.0b013e3181f96282](https://doi.org/10.1212/WNL.0b013e3181f96282)
11. Huse JT, Diamond EL, Wang L, Rosenblum MK (2015) Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true “oligoastrocytoma”? *Acta Neuropathol (Berl)* 129:151–153. doi:[10.1007/s00401-014-1359-y](https://doi.org/10.1007/s00401-014-1359-y)
12. Idbaih A, Ducray F, Dehais C, Courdy C, Carpentier C, de Bernard S, Uro-Coste E, Mokhtari K, Jouvet A, Honnorat J, Chinot O, Ramirez C, Beauchesne P, Benouaich-Amiel A, Godard J, Eimer S, Parker F, Lechapt-Zalcman E, Colin P, Loussouarn D, Faillot T, Dam-Hieu P, Elouadhani-Hamdi S, Bauchet L, Langlois O, Le Guerinel C, Fontaine D, Vauleon E, Menei P, Fotso MJM, Desenclos C, Verrelle P, Verelle P, Ghiringhelli F, Noel G, Labrousse F, Carpentier A, Dhermain F, Delattre J-Y, Figarella-Branger D, POLA Network (2012) SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. *PLoS One* 7:e45950. doi:[10.1371/journal.pone.0045950](https://doi.org/10.1371/journal.pone.0045950)
13. Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard M-A, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon J-M,

- Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre J-Y, Hoang-Xuan K (2007) Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. *Neurology* 68:1831–1836. doi:[10.1212/01.wnl.0000262034.26310.a2](https://doi.org/10.1212/01.wnl.0000262034.26310.a2)
14. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovannella BC, Grollman AP, He T-C, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih I-M, Theodorescu D, Torbenson MS, Velculescu VE, Wang T-L, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. *Proc Natl Acad Sci USA* 110:6021–6026. doi:[10.1073/pnas.1303607110](https://doi.org/10.1073/pnas.1303607110)
 15. Labussière M, Idbaih A, Wang X-W, Marie Y, Boisselier B, Falet C, Paris S, Laffaire J, Carpentier C, Crinière E, Ducray F, El Hallani S, Mokhtari K, Hoang-Xuan K, Delattre J-Y, Sanson M (2010) All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. *Neurology* 74:1886–1890. doi:[10.1212/WNL.0b013e3181e1cf3a](https://doi.org/10.1212/WNL.0b013e3181e1cf3a)
 16. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol (Berl)* 114:97–109. doi:[10.1007/s00401-007-0243-4](https://doi.org/10.1007/s00401-007-0243-4)
 17. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, Figarella-Branger D, Fuller GN, Giangaspero F, Giannini C, Hawkins C, Kleihues P, Korshunov A, Kros JM, Beatriz Lopes M, Ng H-K, Ohgaki H, Paulus W, Pietsch T, Rosenblum M, Rushing E, Soylemezoglu F, Wiestler O, Wesseling P, International Society Of Neuropathology-Haarlem (2014) International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. *Brain Pathol Zurich Switz* 24:429–435. doi:[10.1111/bpa.12171](https://doi.org/10.1111/bpa.12171)
 18. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol (Berl)*. doi:[10.1007/s00401-016-1545-1](https://doi.org/10.1007/s00401-016-1545-1)
 19. Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR, Armstrong TS, Sulman EP, Cahill DP, Vera-Bolanos E, Yuan Y, Reijneveld JC, Ylstra B, Wesseling P, Aldape KD (2015) IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. *Acta Neuropathol (Berl)* 129:585–596. doi:[10.1007/s00401-015-1398-z](https://doi.org/10.1007/s00401-015-1398-z)
 20. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu I-M, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Hartigan J, Smith DR, Strausberg RL, Marie SKN, Shinjo SMO, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. *Science* 321:1807–1812. doi:[10.1126/science.1164382](https://doi.org/10.1126/science.1164382)
 21. Reuss DE, Kratz A, Sahm F, Capper D, Schrimpf D, Koelsche C, Hovestadt V, Bewerunge-Hudler M, Jones DTW, Schittenhelm J, Mittelbronn M, Rushing E, Simon M, Westphal M, Unterberg A, Platten M, Paulus W, Reifenberger G, Tonn J-C, Aldape K, Pfister SM, Korshunov A, Weller M, Herold-Mende C, Wick W, Brandner S, von Deimling A (2015) Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. *Acta Neuropathol (Berl)* 130:407–417. doi:[10.1007/s00401-015-1454-8](https://doi.org/10.1007/s00401-015-1454-8)
 22. Reuss DE, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A, Sahm F, Koelsche C, Korshunov A, Olar A, Hartmann C, Reijneveld JC, Wesseling P, Unterberg A, Platten M, Wick W, Herold-Mende C, Aldape K, von Deimling A (2015) IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. *Acta Neuropathol (Berl)* 129:867–873. doi:[10.1007/s00401-015-1438-8](https://doi.org/10.1007/s00401-015-1438-8)
 23. Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DTW, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. *Acta Neuropathol (Berl)* 129:133–146. doi:[10.1007/s00401-014-1370-3](https://doi.org/10.1007/s00401-014-1370-3)
 24. Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S, Jones DTW, Pfister SM, Herold-Mende C, Wick W, Mueller W, Hartmann C, Paulus W, von Deimling A (2014) Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. *Acta Neuropathol (Berl)* 128:551–559. doi:[10.1007/s00401-014-1326-7](https://doi.org/10.1007/s00401-014-1326-7)
 25. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre J-Y (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. *J Clin Oncol Off J Am Soc Clin Oncol* 27:4150–4154. doi:[10.1200/JCO.2009.21.9832](https://doi.org/10.1200/JCO.2009.21.9832)
 26. Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. *J Clin Oncol Off J Am Soc Clin Oncol* 18:636–645
 27. Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, Shimamura T, Niida A, Motomura K, Ohka F, Yamamoto T, Tanahashi K, Ranjit M, Wakabayashi T, Yoshizato T, Kataoka K, Yoshida K, Nagata Y, Sato-Osubo A, Tanaka H, Sanada M, Kondo Y, Nakamura H, Mizoguchi M, Abe T, Muragaki Y, Watanabe R, Ito I, Miyano S, Natsume A, Ogawa S (2015) Mutational landscape and clonal architecture in grade II and III gliomas. *Nat Genet* 47:458–468. doi:[10.1038/ng.3273](https://doi.org/10.1038/ng.3273)
 28. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. *N Engl J Med* 360:765–773. doi:[10.1056/NEJMoa0808710](https://doi.org/10.1056/NEJMoa0808710)